August 13, 2002 |
Inamed Corp., the maker of a surgical device to treat obesity, said it's reviewing the way it accounted for debt, taxes and warranties for breast implants and may have costs of as much as $10.5 million. The announcement, made after the markets closed, sent shares of the Santa Barbara-based company down as much as $4.19, or 23%, to $14.22 in after-hours trading. They had closed up 11 cents at $18.41 on Nasdaq.
May 23, 2003 |
Inamed Corp.'s 2000 agreement with a Johnson & Johnson unit to resolve a patent and royalties dispute over an obesity treatment was a valid contract, a federal appeals court concluded. The appellate court decided that a federal judge in Los Angeles had erred in concluding that the agreement with Dr. Lubomyr Kuzmak and Ethicon Endo-Surgery was not a binding contract, Inamed Vice President Peter Nicholson said. Ethicon is a Johnson & Johnson unit.
January 8, 2004 |
Inamed Corp. of Santa Barbara, a maker of medical devices seeking to sell the first silicone-gel breast implant in the U.S. in 11 years, said it received a "not approvable" letter from the Food and Drug Administration. The letter outlines what information Inamed must provide to the FDA on silicone-gel breast implants, the company said.
April 24, 2004 |
Inamed Corp. and its partner Genzyme Corp. won Food and Drug Administration approval of the Hylaform gel to treat wrinkles around the eyes and mouth. Inamed, which already sells other wrinkle fillers, will compete with Medicis Pharmaceutical Corp.'s Restylane, which won U.S. approval in December. Shares of Santa Barbara-based Inamed rose $2 to $55.50 on Nasdaq. Genzyme shares fell 64 cents to $46.46, also on Nasdaq.
December 16, 2005 |
Inamed Corp. said its board had unanimously approved Botox maker Allergan Inc.'s $3.2-billion offer in a deal that would allow Allergan to expand its wrinkle-treatment product line. Inamed, which also makes breast implants, said it hadn't signed the agreement, which wouldn't be finalized until Irvine-based Allergan said it was satisfied with its investigation of Inamed's wrinkle smoother Juvederm. Santa Barbara-based Inamed this week agreed to pay a $90-million breakup fee to end its $2.
December 3, 2004 |
Inamed Corp. of Santa Barbara won Food and Drug Administration approval for Captique, an injectable gel to combat facial wrinkles. The product uses hyaluronic acid, a substance that naturally occurs in skin, to plump out wrinkles. Inamed's first-generation hyaluronic gel, Hylaform, was made from ground rooster combs. Captique does not contain animal products. The gels compete with Medicis Pharmaceutical Corp.'s Restylane and are alternatives to collagen, Inamed's mainstay wrinkle treatment.